Clin Exp Otorhinolaryngol.  2018 Mar;11(1):1-8. 10.21053/ceo.2017.00717.

Comparison of Treatment Outcomes for T3 Glottic Squamous Cell Carcinoma: A Meta-Analysis

• Kim BH
• Park SJ
• Jeong WJ
• Ahn SH

• KMID: 2407785
• DOI: http://doi.org/10.21053/ceo.2017.00717

Abstract

OBJECTIVES
This study compared the survival outcomes, local control rate, and laryngeal preservation rate of various treatment strategies in the treatment of T3 squamous cell carcinoma of the glottis using proportional meta-analyses.
METHODS
Twenty-five retrospective case-series studies were included in these analyses. Treatment strategies were classified as total laryngectomy (TL), open partial laryngectomy (PL), transoral laser microsurgery (TLM), chemo-radiation therapy (CRT), and radiation therapy (RT) alone.
RESULTS
The overall survival rate and disease-specific survival rate among laryngeal preservation treatments did not differ from the overall survival rate of TL. However, the local control rate was lower with RT than TL and PL, and laryngeal preservation rates of TLM and CRT were higher than RT alone.
CONCLUSION
Consideration of preservation of laryngeal function is necessary when treating T3 glottic squamous cell carcinoma. PL, TLM, and, CRT are considered more appropriate initial laryngeal preservation strategies if available.

Keyword

Squamous Cell Carcinoma; Glottis; Survival; Organ Preservation; Meta-Analysis

MeSH Terms

Carcinoma, Squamous Cell*
Epithelial Cells*
Glottis
Laryngectomy
Microsurgery
Organ Preservation
Retrospective Studies
Survival Rate

Figure

• 

  Fig. 1. Flow chart of studies through the review.

• 

  Fig. 2. A proportional meta-analysis of case series studies comparing overall survival rate after primary treatments in patients with T3 glottic squamous cell carcinoma.

• 

  Fig. 3. A proportional meta-analysis of case series studies comparing disease-specific survival rate after primary treatments in patients with T3 glottic squamous cell carcinoma.

• 

  Fig. 4. A proportional meta-analysis of case series studies comparing local control rate after primary treatments in patients with T3 glottic squamous cell carcinoma.

• 

  Fig. 5. A proportional meta-analysis of case series studies comparing laryngeal preservation rate after primary treatments in patients with T3 glottic squamous cell carcinoma.

Reference

1. Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006; Sep. 116(9 Pt 2 Suppl 111):1–13.

2. Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991; Jun. 324(24):1685–90.

3. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013; Mar. 31(7):845–52.

4. McNeil BJ, Weichselbaum R, Pauker SG. Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. N Engl J Med. 1981; Oct. 305(17):982–7.

5. Fu X, Zhou Q, Zhang X. Efficacy comparison between total laryngectomy and nonsurgical organ-preservation modalities in treatment of advanced stage laryngeal cancer: a meta-analysis. Medicine (Baltimore). 2016; Apr. 95(14):e3142.

6. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; Nov. 349(22):2091–8.

7. Korean Society of Thyroid-Head and Neck Surgery Guideline Task Force, Ahn SH, Hong HJ, Kwon SY, Kwon KH, Roh JL, et al. Guidelines for the Surgical Management of Laryngeal Cancer: Korean Society of Thyroid-Head and Neck Surgery. Clin Exp Otorhinolaryngol. 2017; Mar. 10(1):1–43.

8. Mantsopoulos K, Psychogios G, Bohr C, Zenk J, Kapsreiter M, Waldfahrer F, et al. Primary surgical treatment of T3 glottic carcinoma: long-term results and decision-making aspects. Laryngoscope. 2012; Dec. 122(12):2723–7.

9. American Society of Clinical Oncology, Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006; Aug. 24(22):3693–704.

10. Canis M, Ihler F, Martin A, Wolff HA, Matthias C, Steiner W. Results of 226 patients with T3 laryngeal carcinoma after treatment with transoral laser microsurgery. Head Neck. 2014; May. 36(5):652–9.

11. Megwalu UC, Sikora AG. Survival outcomes in advanced laryngeal cancer. JAMA Otolaryngol Head Neck Surg. 2014; Sep. 140(9):855–60.

12. Hartl DM, Ferlito A, Brasnu DF, Langendijk JA, Rinaldo A, Silver CE, et al. Evidence-based review of treatment options for patients with glottic cancer. Head Neck. 2011; Nov. 33(11):1638–48.

13. Edge S, Byrd DR, Compton CC, Fritz AG, Greene F, Trotti A. AJCC cancer staging handbook. 7th ed. New York: Springer;2010.

14. Weller MD, Nankivell PC, McConkey C, Paleri V, Mehanna HM. The risk and interval to malignancy of patients with laryngeal dysplasia; a systematic review of case series and meta-analysis. Clin Otolaryngol. 2010; Oct. 35(5):364–72.

15. El Dib R, Nascimento Junior P, Kapoor A. An alternative approach to deal with the absence of clinical trials: a proportional meta-analysis of case series studies. Acta Cir Bras. 2013; Dec. 28(12):870–6.

16. Luo XN, Chen LS, Zhang SY, Lu ZM, Huang Y. Effectiveness of chemotherapy and radiotherapy for laryngeal preservation in advanced laryngeal cancer: a meta-analysis and systematic review. Radiol Med. 2015; Dec. 120(12):1153–69.

17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; Sep. 315(7109):629–34.

18. Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and forest plots using a Microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012; Jan. 5:52.

19. Porter MJ, McIvor NP, Morton RP, Hindley AC. Audit in the management of T3 fixed-cord laryngeal cancer. Am J Otolaryngol. 1998; Nov-Dec. 19(6):360–4.

20. Kowalski LP, Batista MB, Santos CR, Scopel A, Salvajolli JV, Torloni H. Prognostic factors in T3,N0-1 glottic and transglottic carcinoma: a multifactorial study of 221 cases treated by surgery or radiotherapy. Arch Otolaryngol Head Neck Surg. 1996; Jan. 122(1):77–82.

21. Foote RL, Olsen KD, Buskirk SJ, Stanley RJ, Suman VJ. Laryngectomy alone for T3 glottic cancer. Head Neck. 1994; Sep-Oct. 16(5):406–12.

22. Simpson D, Robertson AG, Lamont D. A comparison of radiotherapy and surgery as primary treatment in the management of T3 N0 M0 glottic tumours. J Laryngol Otol. 1993; Oct. 107(10):912–5.

23. Woodhouse RJ, Quivey JM, Fu KK, Sien PS, Dedo HH, Phillips TL. Treatment of carcinoma of the vocal cord: a review of 20 years experience. Laryngoscope. 1981; Jul. 91(7):1155–62.

24. Harwood AR, Hawkins NV, Beale FA, Rider WD, Bryce DP. Management of advanced glottic cancer: a 10 year review of the Toronto experience. Int J Radiat Oncol Biol Phys. 1979; Jun. 5(6):899–904.

25. Nakayama M, Miyamoto S, Seino Y, Okamoto T, Kano K, Hasebe M, et al. One hundred supracricoid laryngectomies with cricohyoidoepiglottopexy: do we achieve better local control? Jpn J Clin Oncol. 2015; Aug. 45(8):732–7.

26. Leszczynska M, Wierzbicka M, Tokarski M, Szyfter W. Attempt to improve functional outcomes in supracricoid laryngectomy in T2b and T3 glottic cancers. Eur Arch Otorhinolaryngol. 2015; Oct. 272(10):2925–31.

27. Day AT, Sinha P, Nussenbaum B, Kallogjeri D, Haughey BH. Management of primary T1-T4 glottic squamous cell carcinoma by transoral laser microsurgery. Laryngoscope. 2017; Mar. 127(3):597–604.

28. Ansarin M, Cattaneo A, De Benedetto L, Zorzi S, Lombardi F, Alterio D, et al. Retrospective analysis of factors influencing oncologic outcome in 590 patients with early-intermediate glottic cancer treated by transoral laser microsurgery. Head Neck. 2017; Jan. 39(1):71–81.

29. Peretti G, Piazza C, Penco S, Santori G, Del Bon F, Garofolo S, et al. Transoral laser microsurgery as primary treatment for selected T3 glottic and supraglottic cancers. Head Neck. 2016; Jul. 38(7):1107–12.

30. Breda E, Catarino R, Monteiro E. Transoral laser microsurgery for laryngeal carcinoma: survival analysis in a hospital-based population. Head Neck. 2015; Aug. 37(8):1181–6.

31. Pantazis D, Liapi G, Kostarelos D, Kyriazis G, Pantazis TL, Riga M. Glottic and supraglottic pT3 squamous cell carcinoma: outcomes with transoral laser microsurgery. Eur Arch Otorhinolaryngol. 2015; Aug. 272(8):1983–90.

32. Vilaseca I, Bernal-Sprekelsen M, Luis Blanch J. Transoral laser microsurgery for T3 laryngeal tumors: prognostic factors. Head Neck. 2010; Jul. 32(7):929–38.

33. Motta G, Esposito E, Motta S, Tartaro G, Testa D. CO2 laser surgery in the treatment of glottic cancer. Head Neck. 2005; Aug. 27(8):733.

34. Hinerman RW, Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB. T3 and T4 true vocal cord squamous carcinomas treated with external beam irradiation: a single institution’s 35-year experience. Am J Clin Oncol. 2007; Apr. 30(2):181–5.

35. Murakami R, Nishimura R, Baba Y, Yumoto E, Oya N, Yamashita Y. Concurrent chemoradiation therapy with low-dose CDDP and UFT for glottic carcinomas: evaluation using the sixth edition of the UICC TNM staging system. Acta Oncol. 2006; 45(2):162–7.

36. Jorgensen K, Godballe C, Hansen O, Bastholt L. Cancer of the larynx: treatment results after primary radiotherapy with salvage surgery in a series of 1005 patients. Acta Oncol. 2002; 41(1):69–76.

37. MacKenzie RG, Franssen E, Balogh JM, Gilbert RW, Birt D, Davidson J. Comparing treatment outcomes of radiotherapy and surgery in locally advanced carcinoma of the larynx: a comparison limited to patients eligible for surgery. Int J Radiat Oncol Biol Phys. 2000; Apr. 47(1):65–71.

38. Mendenhall WM, Parsons JT, Mancuso AA, Pameijer FJ, Stringer SP, Cassisi NJ. Definitive radiotherapy for T3 squamous cell carcinoma of the glottic larynx. J Clin Oncol. 1997; Jun. 15(6):2394–402.

39. Wang CC. Factors influencing the success of radiation therapy for T2 and T3 glottic carcinomas: importance of cord mobility and sex. Am J Clin Oncol. 1986; Dec. 9(6):517–20.

40. Furusaka T, Matsuda A, Tanaka A, Matsuda H, Ikeda M. Superselective intra-arterial chemoradiation therapy for functional laryngeal preservation in advanced squamous cell carcinoma of the glottic larynx. Acta Otolaryngol. 2013; Jun. 133(6):633–40.

41. Lin C, Sia E, Keller J. Concurrent chemoradiation for T3 glottic squamous cell carcinoma: a reasonable alternative to upfront laryngectomy. Adv Cancer Res Treat. 2012; Dec. 2012:461217. https://doi.org/10.5171/2012.461217.

42. Chen AY, Fedewa S, Zhu J. Temporal trends in the treatment of early- and advanced-stage laryngeal cancer in the United States, 1985-2007. Arch Otolaryngol Head Neck Surg. 2011; Oct. 137(10):1017–24.

43. O’Neill CB, O’Neill JP, Atoria CL, Baxi SS, Henman MC, Ganly I, et al. Treatment complications and survival in advanced laryngeal cancer: a population-based analysis. Laryngoscope. 2014; Dec. 124(12):2707–13.

44. Laccourreye H, Laccourreye O, Weinstein G, Menard M, Brasnu D. Supracricoid laryngectomy with cricohyoidopexy: a partial laryngeal procedure for selected supraglottic and transglottic carcinomas. Laryngoscope. 1990; Jul. 100(7):735–41.

45. Al-Gilani M, Skillington SA, Kallogjeri D, Haughey B, Piccirillo JF. Surgical vs nonsurgical treatment modalities for T3 glottic squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2016; Oct. 142(10):940–6.

46. Weinstein GS, El-Sawy MM, Ruiz C, Dooley P, Chalian A, El-Sayed MM, et al. Laryngeal preservation with supracricoid partial laryngectomy results in improved quality of life when compared with total laryngectomy. Laryngoscope. 2001; Feb. 111(2):191–9.